1. Home
  2. NCV vs ATYR Comparison

NCV vs ATYR Comparison

Compare NCV & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Virtus Convertible & Income Fund of Beneficial Interest

NCV

Virtus Convertible & Income Fund of Beneficial Interest

HOLD

Current Price

$14.96

Market Cap

350.4M

Sector

Finance

ML Signal

HOLD

Logo aTyr Pharma Inc.

ATYR

aTyr Pharma Inc.

HOLD

Current Price

$0.71

Market Cap

79.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NCV
ATYR
Founded
2003
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
350.4M
79.2M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
NCV
ATYR
Price
$14.96
$0.71
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
$8.75
AVG Volume (30 Days)
405.1K
2.3M
Earning Date
01-01-0001
11-06-2025
Dividend Yield
12.48%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$190,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$18,728.88
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.84
$0.64
52 Week High
$3.59
$7.29

Technical Indicators

Market Signals
Indicator
NCV
ATYR
Relative Strength Index (RSI) 42.50 37.66
Support Level $14.76 $0.70
Resistance Level $15.56 $0.83
Average True Range (ATR) 0.18 0.05
MACD -0.05 0.01
Stochastic Oscillator 23.81 8.21

Price Performance

Historical Comparison
NCV
ATYR

About NCV Virtus Convertible & Income Fund of Beneficial Interest

Virtus Convertible & Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and high current income. It intends to achieve the objective by investing in a portfolio of domestic convertible securities and non-convertible income-producing securities. Its portfolio of investments includes Software, the Internet, the Commercial Services sector in the form of Convertible Bonds and Notes, and Media, Oil, Gas & Consumable Fuels, and Entertainment sector in the form of Corporate Bonds and Notes.

About ATYR aTyr Pharma Inc.

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

Share on Social Networks: